Related Experiment Video

Updated: Oct 13, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Cardiac transplantation: the final therapeutic option for the treatment of heart failure

M M Koerner1, J B Durand, J A Lafuente

  • 1Baylor College of Medicine, Houston, Texas 77030, USA. mkoerner@bcm.tmc.edu

Current Opinion in Cardiology
|August 22, 2000
PubMed

Insights

End-stage heart failure significantly impacts life quality and prognosis. Cardiac transplantation offers a final therapeutic option, with mechanical support systems aiding patient selection and management.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Medical Technology

Background:

  • End-stage heart failure (EHF) severely diminishes quality of life and patient prognosis.
  • Cardiac transplantation is a definitive treatment for irreversible EHF across all age demographics.
  • Effective management of EHF necessitates advanced therapeutic strategies.

Purpose of the Study:

  • To highlight the critical role of cardiac transplantation in managing end-stage heart failure.
  • To emphasize the importance of interdisciplinary teams in candidate selection and management.
  • To underscore the utility of mechanical circulatory support systems in heart transplantation.

Main Methods:

  • Review of current practices in cardiac transplantation for end-stage heart failure.
  • Analysis of the role of interdisciplinary teams in patient selection.
  • Evaluation of mechanical circulatory support systems for bridging and recovery.

Main Results:

  • Cardiac transplantation remains a vital option for end-stage heart failure patients.
  • Experienced interdisciplinary teams enhance candidate selection and management of complex cases.
  • Mechanical circulatory support systems are crucial for bridging to transplant and potential recovery.

Conclusions:

  • Cardiac transplantation is a key therapy for end-stage heart failure.
  • Interdisciplinary expertise and mechanical circulatory support are essential for successful transplantation outcomes.
  • Optimized patient selection and support improve the prognosis for heart failure patients.

More Related Videos

A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model06:52

A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model

Published on: November 4, 2025

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death07:08

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

Published on: June 6, 2025

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...